Brain Metastases, Adult Clinical Trial
Official title:
A Phase 1, Sequential Cohort, Open-Label, Dose-Escalation Study of the Safety and CNS Exposure of Pritumumab in Patients With Brain Cancer
Pritumumab is a human IgG1 kappa antibody that binds to a malignant tumor associated antigen, ecto domain-vimentin (EDV) which is expressed in a variety of tumor cells. Pritumumab was shown to have relatively high reactivity with brain cancer cell lines, while no reactivity was demonstrated with normal neurons, astrocytes or fetal cerebral cells. Pritumumab has notable antibody-dependent cellular cytotoxicity (ADCC), brain tumor penetration and antitumor activity in nude mouse human xenograft models. Primary Objectives - To determine the safety and/or tolerability and the recommended Phase 2 dose (RP2D) of escalating, intravenously (IV) administered Pritumumab doses in patients with recurrent gliomas or with brain metastases. Secondary Objectives - To determine pharmacokinetics and pharmacodynamics of Pritumumab - To identify preliminary signals of anti-tumor response to Pritumumab - To explore disease-related, patient-reported outcomes
This is an open-label, Phase 1, outpatient, dose escalation study of Pritumumab in patients with brain cancer who have failed prior therapy and have no other available options. In the first part of the study, escalating doses of Pritumumab of 1.6, 4.8, 8.0, 12.0, and 16.2 mg/kg will be administered in a sequential, safety-driven manner to eligible patients according to standard 3+3 scheme, as an 1-hour IV infusion on Days 1, 8, 15, and 22 of each 28-day treatment cycle. The dose levels may be modified upon obtained results. Once the maximum tolerated dose (MTD) is determined, an expansion cohort including 6-12 patients in selected tumor type at a dose equal or below to MTD is planned to determine the recommended Phase 2 dose (RP2D). A total of 42 patients may be administered with Pritumumab in this study. Patients will be treated with Pritumumab for a maximum of 6 cycles or until cancer progression or unacceptable toxicity. Patients will be followed after treatment completion every four months or until death or lost to follow-up. Standard clinical, laboratory and functional assessments will be employed to monitor for safety, tolerability and tumor response, including blood sampling for clinical biochemistries, pharmacokinetics, CSF and tissue samples, at frequency specified by the protocol. Patient-reported outcomes will also be assessed. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05428852 -
Keto-Brain:Investigating the Use of Ketogenic Diets in Brain Metastases
|
N/A | |
Recruiting |
NCT05559853 -
Developing a New MRI Technique to Understand Changes in Brain Tumors After Treatment
|
||
Recruiting |
NCT05689619 -
SILibinin in NSCLC and BC Patients With Single Brain METastasis (SILMET)
|
N/A | |
Recruiting |
NCT04197297 -
Brain Imaging Biomarkers in Patients With Brain Metastasis
|
Phase 2 | |
Recruiting |
NCT04397978 -
Local Ablative Therapy for Patients With Multiple (4-10) Brain Metastases
|
||
Terminated |
NCT04434560 -
Neoadjuvant Immunotherapy in Brain Metastases
|
Phase 2 | |
Active, not recruiting |
NCT05095766 -
Comparaison Between MRI Alone or Combined With Positron Emission Tomography for Brain Metastasis Diagnosis
|
||
Recruiting |
NCT05012254 -
Nivolumab and Ipilimumab Plus Chemotherapy for Patients With Stage IV Lung Cancer With Brain Metastases
|
Phase 2 | |
Recruiting |
NCT05789589 -
Effect of Azeliragon Combined With Stereotactic Radiation Therapy in Patients With Brain Metastases
|
Phase 1/Phase 2 | |
Recruiting |
NCT06280300 -
Multi-disciplinary Care for Brain Metastases
|
N/A | |
Recruiting |
NCT06047379 -
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
|
Phase 1/Phase 2 | |
Completed |
NCT03896555 -
Intrafractional Head Movement During Radiosurgery
|
||
Terminated |
NCT03789149 -
Focal Intraoperative Radiotherapy of Brain Metastases
|
Phase 2 | |
Recruiting |
NCT04343157 -
UCSD Image-Guided Cognitive-Sparing Radiosurgery for Brain Metastases
|
Phase 2 | |
Recruiting |
NCT04711824 -
Study of Stereotactic Radiosurgery With Olaparib Followed by Durvalumab and Physician's Choice Systemic Therapy in Subjects With Breast Cancer Brain Metastases
|
Phase 1/Phase 2 | |
Recruiting |
NCT05793489 -
Prospective Double Arm Randomized Trial: WBRT Alone and WBRT Plus Silibinin
|
N/A | |
Recruiting |
NCT04461418 -
Accelerated Checkpoint Therapy for Any Steroid Dependent Patient With Brain Metastases
|
Phase 2 | |
Active, not recruiting |
NCT03818386 -
Radiotherapy of Multiple Brain Metastases Using AGuIX®
|
Phase 2 | |
Active, not recruiting |
NCT05087095 -
Managing Distress in Malignant Brain Cancer
|
N/A | |
Recruiting |
NCT06231186 -
a Feasibility Study of iHD-SRT for BM
|
N/A |